Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 14:50:101338.
doi: 10.1016/j.ijcha.2024.101338. eCollection 2024 Feb.

Mortality prognosis of NGAL, NTproBNP, hsTnT, and GRACE score in patients with acute coronary syndrome

An Viet Tran  1   2 , Nguyet To Tran  3 , Khue Duy Nguyen  2 , Diem Thi Nguyen  1 , Toan Hoang Ngo  1
Affiliations

Mortality prognosis of NGAL, NTproBNP, hsTnT, and GRACE score in patients with acute coronary syndrome

An Viet Tran et al. Int J Cardiol Heart Vasc. .

Abstract

Background: NGAL serum concentration have predictive value for cardiovascular events and mortality in patients with acute coronary syndrome (ACS).

Objectives: Assessed the all-cause mortarlity prognosis value of serum neutrophil gelatinase-associated lipocalin (NGAL), combination with N-terminal pro B-type natriuretic peptide (NT-proBNP), and hsTnT, and GRACE score in patients with ACS.

Materials and methods: We conducted a cross-sectional analysis study used in this study in 58 patients with ACS. Serum NGAL, NT-proBNP, hs-TnT concentration and GRACE score associated with death events (after 3 months of follow-up) were assessed by receiver operating characteristic (ROC) curve.

Results: High performance in predicting mortality of NGAL with a cut-off value of 154.55 ng/mL (AUC, 95% CI = 0.96, 0.90 - 1.0; p = 0.001), GRACE score with 140.50 scores (AUC, 95% CI = 0.76, 0.57 - 0.96; p = 0.051). Combination of NTproBNP plus NGAL indicated with the highest value (AUC, 95% CI = 0.96, 0.91 - 1.0; Se = 80.0; Sp = 92.5; p = 0.001). The relative risk assessment indicated a high value in mortality prediction of NGAL with a cut-off value of 154.55 (OR, 95% CI = 49.0, 4.3 - 549.2; p < 0.001), and GRACE score with 140.50 scores (OR, 95% CI = 11.1, 1.1 - 108.4; p = 0.013).

Conclusion: NGAL can be employed as a biomarker for the early prediction of mortality events in individuals with ACS. The combination of NGAL, NT-proBNP, hsTnT, and GRACE score showed the higher outcome but not worth mentioning.

Keywords: Acute coronary syndromes; High sensitivity troponin T; Mortality assessment; Neutrophil Gelatinase-Associated Lipocalin; Pro B-type Natriuretic Peptide.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Toan Hoang Ngo reports financial support was provided by Vingroup Joint Stock Company. Toan Hoang Ngo reports a relationship with Vingroup Joint Stock Company that includes: funding grants. Toan Hoang Ngo has patent the Master, PhD Scholarship Programme of Vingroup Innovation Foundation (pending to VINIF.2023.TS.132. Toan Hoang Ngo was funded by the Master, PhD Scholarship Programme of Vingroup Innovation Foundation (VINIF), code VINIF.2023.TS.132. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Participants flow of the study.
Fig. 2
Fig. 2
Receiver operating characteristic (ROC) curve showed the mortality predictive performance of (A) Model 1 and (B) Model 2. hsCRP: high-sensitivity C-reactive protein, NGAL: Neutrophil gelatinase-associated lipocalin, hs-TnT: High-sensitivity troponin T, NT-proBNP: N-terminal pro B-type natriuretic peptide, GRACE: Global Registry of Acute Coronary Event.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Official Statistics of Sweden Health and Medical Care. Statistics on Myocardial Infarctions, https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelk... 2020 [accessed 13 March 2023].
    1. Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J. Am. Coll. Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010. - DOI - PMC - PubMed
    1. M. Buonafine, E. Martinez-Martinez, F. Jaisser, More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clin. Sci. (London, England : 1979). 2018;132(9):909-23. 10.1042/CS20171592. - PubMed
    1. Woitas R.P., Scharnagl H., Kleber M.E., Delgado G.E., Grammer T.B., Pichler M., et al. Neutrophil gelatinase-associated lipocalin levels are U-shaped in the ludwigshafen risk and cardiovascular health (LURIC) study-impact for mortality. PLoS One. 2017;12(2):e0171574. - PMC - PubMed
    1. Helanova K., Littnerova S., Kubena P., Ganovska E., Pavlusova M., Kubkova L., et al. Prognostic impact of neutrophil gelatinase-associated lipocalin and B-type natriuretic in patients with ST-elevation myocardial infarction treated by primary PCI: a prospective observational cohort study. BMJ Open. 2015;5(10):e006872. - PMC - PubMed